Skip to main content
SpringerLink
Log in

Chemoprevention of Upper Aerodigestive Tract Cancer

Clinical Trials and Future Directions

  • Chapter
Cancer Chemoprevention

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 834 Accesses

Abstract

Head and neck cancer is a major cause of cancer-related deaths (1). In the United States alone, head and neck cancer is the fifth most common cancer, with approximately 45,400 cases anticipated for the year 2002 and approx 12,600 deaths. We expect that more than 600,000 cases of head and neck cancer will have been diagnosed worldwide in the year 2002 (2). The complexity of head and neck cancer treatment relates to substantial progress in surgery, concomitant chemoradiation therapy, and intensity-modulated radiotherapy over the past few decades. At least six active chemotherapeutic agents are available for this disease, but the 5-yr survival rate has improved only slightly since the 1960s. The overwhelming functional consequences of this disease, its effect on daily life (including problems with speech, swallowing, and profound cosmetic defects), and the subsequent loss of self-esteem and social status make it a particularly serious illness. Further, patients fortunate enough to be cured of head and neck cancer often succumb to a second smoking-related cancer. In addition, metachronous primary cancers in this high-risk group continue to confound care providers. Some studies indicate that these cancers are major determinants of overall prognosis in patients definitively treated for early-stage disease (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15–36.

    Article  PubMed  CAS  Google Scholar 

  2. Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In Cancer Medicine. Holland JF, Bast RC, Morton DL, et al., eds. Williams & Wilkins, Baltimore, 1997; pp. 1645–1710.

    Google Scholar 

  3. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 1984;110:564–565.

    PubMed  CAS  Google Scholar 

  4. Cooper JS, Pajak TK, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449–456.

    PubMed  CAS  Google Scholar 

  5. Licciardello JT, Spitz MR, Hong WK. Multiple primary cancers in patients with cancer of the head and neck: second cancer of the head and neck, esophagus and lung. Int J Radiat Oncol Biol Phys 1989;17:467–476.

    PubMed  CAS  Google Scholar 

  6. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488–2492.

    PubMed  CAS  Google Scholar 

  7. Bergen AW, Caporaso N. Cigarette smoking. J Natl Cancer Inst 1999;91:1365–1375.

    Article  PubMed  CAS  Google Scholar 

  8. Dominioni L, Strauss GM, Imperatori A, et al. Screening for lung cancer. Chest Surg Clin N Am 2000;10:729–736.

    PubMed  CAS  Google Scholar 

  9. Kurie JM, Spitz MR, Hong WK. Lung cancer chemoprevention: targeting former rather than current smokers. Cancer Prev International 1995;2:55–58.

    Google Scholar 

  10. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430–432.

    Article  PubMed  CAS  Google Scholar 

  11. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1976;6:820–824.

    Google Scholar 

  12. Carey TE, Frank CJ, Raval JR, et al. Identifying genetic changes associated with tumor progression in squamous cell carcinoma. Acta Otolaryngol (Stockh) 1997;529:229–232.

    Article  CAS  Google Scholar 

  13. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994;54:1156–1158.

    PubMed  Google Scholar 

  14. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682–685.

    Article  PubMed  CAS  Google Scholar 

  15. Hung J, Kishimoto Y, Sujio K, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma [published erratum appears in JAMA 1995;273:1908]. JAMA 1995;273:558–563.

    Article  PubMed  CAS  Google Scholar 

  16. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963–968.

    Article  PubMed  CAS  Google Scholar 

  17. Auerbach O, Gere JB, Forman JB, et al. Changes in bronchial epithelium in relation to smoking and cancer of the lungs: a report of progress. N Engl J Med 1957;256:97–104.

    PubMed  CAS  Google Scholar 

  18. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs 1970–1977. N Engl J Med 1979;300:381–385.

    PubMed  CAS  Google Scholar 

  19. Gao X, Fisher SG, Mohideen N, et al. Second primary cancers in patients with laryngeal cancer: a population-based study [Abstract]. Proc Am Soc Clin Oncol 2000;19:414a.

    Google Scholar 

  20. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 1997;89:1782–1788.

    Article  PubMed  CAS  Google Scholar 

  21. Russo A, Crosignani P, Berrino F. Tobacco smoking, alcohol drinking and dietary factors as determinants of new primaries among male laryngeal cancer patients: a case-cohort study. Tumori 1996;82:519–525.

    PubMed  CAS  Google Scholar 

  22. Kurokawa R, DiRenzo J, Boehm M, et al. Regulation of retinoid signaling by receptor polarity and allosteric control of ligand binding. Nature 1994;371:528–531.

    Article  PubMed  CAS  Google Scholar 

  23. Van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 1995;87:1530–1537.

    Article  PubMed  Google Scholar 

  24. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383–390.

    PubMed  CAS  Google Scholar 

  25. Silverman S Jr, Gorsky M, Greenspan D. Tobacco usage in patients with head and neck carcinomas: a follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 1983;106:33–35.

    PubMed  Google Scholar 

  26. Castigliano SG. Influence of continued smoking on the incidence of second primary cancers involving mouth, pharynx, and larynx. J Am Dent Assoc 1968;77:580–585.

    PubMed  CAS  Google Scholar 

  27. Bedi GC, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996;56:2484–2487.

    PubMed  CAS  Google Scholar 

  28. Leong PP, Rezai B, Koch WM, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998;90:972–977.

    Article  PubMed  CAS  Google Scholar 

  29. Califano J, Leong PL, Koch WM, et al. Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships. Clin Cancer Res 1999;5:1862–1867.

    PubMed  CAS  Google Scholar 

  30. Khuri FR, Rodriguez M, Lee JJ, et al. Comprehensive analysis of clinical and molecular determinants of second events in the randomized retinoid head and neck second primary tumor prevention trial. Proc Am Assoc Cancer Res 2002; abst. 2553.

    Google Scholar 

  31. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332–1338.

    PubMed  CAS  Google Scholar 

  32. Hong W, Endicott J, Itri LM, et al. 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–1505.

    PubMed  CAS  Google Scholar 

  33. Zaridze D, Evstifeeva T, Boyle P. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol 1993;3:225–234.

    Article  PubMed  CAS  Google Scholar 

  34. Stich HF, Rosin MP, Hornby P, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with β-carotene and with β-carotene plus vitamin A. Int J Cancer 1988;42:195–199.

    Article  PubMed  CAS  Google Scholar 

  35. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15–20.

    Article  PubMed  CAS  Google Scholar 

  36. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus β-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 1997;89:257–258.

    Article  PubMed  CAS  Google Scholar 

  37. Han J, Jiao L, Lu Y, et al. Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990;4:153–160.

    PubMed  Google Scholar 

  38. Chiesa F, Tradati N, Marazza M, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR): preliminary results. Eur J Cancer B Oral Oncol 1992;28B:97–102.

    Article  PubMed  CAS  Google Scholar 

  39. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125:1083–1089.

    PubMed  CAS  Google Scholar 

  40. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795–801.

    PubMed  CAS  Google Scholar 

  41. Bolla M, Lefur R, Ton Van J, et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomized study. Eur J Cancer 1994;30A:767–772.

    Article  PubMed  CAS  Google Scholar 

  42. Wolbach SB, Howe PR. Tissue changes following deprivation of fat soluble A vitamin. J Exp Med 1925;42:753.

    Article  CAS  PubMed  Google Scholar 

  43. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In The Retinoids. Sporn MB, Roberts AB, Goodman DS, eds. Raven Press, New York, 1994; pp. 319–349.

    Google Scholar 

  44. Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994;5:115–125.

    Article  PubMed  CAS  Google Scholar 

  45. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signaling pathways. Trends Biochem Sci 1992;17:427–433.

    Article  PubMed  CAS  Google Scholar 

  46. Blaner WS. Biochemistry and pharmacology of retinoids. In Retinoids in Oncology. Hong WK, Lotan R, eds. Marcel Dekker, New York, 1993; pp. 1–42.

    Google Scholar 

  47. Boehm MF, Zhang L. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930–2941.

    Article  PubMed  CAS  Google Scholar 

  48. Khuri FR, Rigas JR, Figlin RA, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:2626–2637.

    PubMed  CAS  Google Scholar 

  49. Oridate N, Lotan D, Xu XC, et al. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 1996;2:855–863.

    PubMed  CAS  Google Scholar 

  50. Xu XC, Zile MH, Lippman SM, et al. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 1995;55:5507–5511.

    PubMed  CAS  Google Scholar 

  51. Silverman S, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984;53:563–568.

    Article  PubMed  Google Scholar 

  52. Stich HR, Rosin MP, Hornby P, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988;42:195–199.

    Article  PubMed  CAS  Google Scholar 

  53. Mao L, El-Naggar AK, Papadimitrakopoulou VA, et al. Molecular paradox of complete phenotypic response of advanced head and neck premalignancies to biochemoprevention. J Natl Cancer Inst 1998;90:1545–1551.

    Article  PubMed  CAS  Google Scholar 

  54. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140–141.

    Article  PubMed  CAS  Google Scholar 

  55. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216–1222.

    PubMed  CAS  Google Scholar 

  56. Van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 2000;92:977–986.

    Article  PubMed  Google Scholar 

  57. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605–618.

    Article  PubMed  CAS  Google Scholar 

  58. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823–829.

    PubMed  CAS  Google Scholar 

  59. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405–1410.

    Article  PubMed  CAS  Google Scholar 

  60. Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994;54:3580–3587.

    PubMed  CAS  Google Scholar 

  61. Xu XC, Sozzi G, Lee JS, et al. Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 1997;89:624–629.

    Article  PubMed  CAS  Google Scholar 

  62. Lippman SM, Shin DM, Lee JJ, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995;55:16–19.

    PubMed  CAS  Google Scholar 

  63. Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997;3:875–880.

    PubMed  CAS  Google Scholar 

  64. Shin DM, Lee JS, Lippman SM, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519–529.

    Article  PubMed  CAS  Google Scholar 

  65. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062–1074.

    Article  PubMed  CAS  Google Scholar 

  66. Kies MS, Clayman GL, El-Naggar AK, et al. Induction therapy with SCH66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck [Abstract]. Proc Am Soc Clin Oncol 2001;20:225a.

    Google Scholar 

  67. Khuri FR, Glisson BS, Meyers ML, et al. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety [Abstract]. Proc Am Soc Clin Oncol 2000;19:205a.

    Google Scholar 

  68. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87–98.

    PubMed  CAS  Google Scholar 

  69. Grandis JR, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284–1292.

    Article  CAS  Google Scholar 

  70. Modjtahedi H, Affleck K, Stubberfield C, et al. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in human squamous cell carcinoma HN5. Int J Oncol 1998;13:335–342.

    PubMed  CAS  Google Scholar 

  71. Baselga J, Averbuch SD. ZD1839 (“Iressa”) as an anti-cancer agent. Drugs 2000;60:33–40.

    Article  PubMed  CAS  Google Scholar 

  72. Sirotnak FM, Zakowiski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885–4892.

    PubMed  CAS  Google Scholar 

  73. Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs 2003;12:1395–1402.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

    Fadlo R. Khuri MD

  2. Department of Cancer Medicine, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

    Edward S. Kim MD

  3. Department of Cancer Medicine, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

    Waun Ki Hong MD

Authors
  1. Fadlo R. Khuri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward S. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Waun Ki Hong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Gary J. Kelloff MD

  2. Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Ernest T. Hawk MD, MPH

  3. CCS Associates, Mountain View, CA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Khuri, F.R., Kim, E.S., Hong, W.K. (2005). Chemoprevention of Upper Aerodigestive Tract Cancer. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-768-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-768-0_28

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-077-9

  • Online ISBN: 978-1-59259-768-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation